NCT07055243View on ClinicalTrials.gov

To Assess Safety of Mitapivat and Provide Proof of Concept of the Efficacy of the Drug in Patients With RBC Membranopathies or CDAII.

PHASE2RecruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

June 26, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2027

Conditions
Anemia
Interventions
DRUG

Mitapivat

Mitapivat will be given to adult patients with erythrocyte membranopathies

Trial Locations (1)

M5G 2C4

RECRUITING

University Health Network (UHN), Toronto

Sponsors
All Listed Sponsors
collaborator

Agios Pharmaceuticals, Inc.

INDUSTRY

lead

University Health Network, Toronto

OTHER